CHRS.NASDAQCoherus Biosciences, INC

8-K: Coherus BioSciences Divests YUSIMRY Franchise for $40 Million in Cash

Sentiment:

Asset Sale Announcement

📋All filings for Coherus Biosciences, INC
🔒Login to Follow

Coherus BioSciences has sold its YUSIMRY franchise to Hong Kong King-Friend Industrial Company Ltd. for $40 million in an all-cash deal, completed on June 26, 2024.

Summary

  • Coherus BioSciences has divested its YUSIMRY (adalimumab-aqvh) franchise to Hong Kong King-Friend Industrial Company Ltd. (HKF) for $40 million in upfront cash.
  • The deal includes the sale of YUSIMRY, related intellectual property, contracts, inventory, and research and development activities.
  • HKF will also assume $17 million in inventory purchase commitments.
  • The transaction closed on June 26, 2024.
  • This divestiture is part of Coherus's strategic shift to focus on oncology.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The divestiture provides cash and allows Coherus to focus on its core oncology business, but it also means the loss of a revenue stream. The strategic shift is viewed positively, but the execution and success of the oncology pipeline will be key.

Positives

  • The $40 million cash infusion will strengthen Coherus's financial position.
  • The divestiture allows Coherus to focus on its oncology business.
  • The sale aligns with Coherus's strategic goals for growth in the oncology sector.
  • The transaction provides resources for Coherus to advance its oncology pipeline.

Negatives

  • Coherus is losing a revenue stream from the YUSIMRY franchise.
  • The company is divesting assets related to a product that was already on the market.

Risks

  • The company is now more reliant on its oncology pipeline for future revenue.
  • There is a risk that the oncology pipeline may not perform as expected.
  • The company may face challenges in transitioning its focus to oncology.
  • The company may face challenges in integrating the Surface Oncology acquisition.

Future Outlook

Coherus intends to use the proceeds from the sale of YUSIMRY to bolster its cash position and advance its efforts to become a sustainable and growing oncology company. The company will focus on its oncology assets, including LOQTORZI, UDENYCA, and its immuno-oncology pipeline.

Management Comments

  • Denny Lanfear, Coherus Chairman and Chief Executive Officer, stated that the divestiture of YUSIMRY reinforces the company's strategic focus on oncology.
  • Lanfear also mentioned that the proceeds from the sale will bolster the company's cash position and advance its efforts to become a sustainable and growing oncology company.

Industry Context

This divestiture reflects a trend in the biopharmaceutical industry where companies are streamlining their portfolios to focus on core therapeutic areas. Coherus is shifting its focus from biosimilars to oncology, which is a high-growth area with significant unmet medical needs. This move is similar to other companies that have divested non-core assets to concentrate on specific therapeutic areas.

Comparison to Industry Standards

  • The divestiture of YUSIMRY is similar to other pharmaceutical companies selling off non-core assets to focus on specific therapeutic areas.
  • The $40 million upfront cash payment is a typical structure for asset sales in the biopharmaceutical industry.
  • The assumption of $17 million in inventory purchase commitments is a common element in such transactions.
  • The focus on oncology is a strategic move that aligns with the industry's trend towards high-growth therapeutic areas.
  • The company's move to focus on its oncology pipeline is similar to other companies that have divested non-core assets to concentrate on specific therapeutic areas.

Stakeholder Impact

  • Shareholders will benefit from the increased cash position and strategic focus on oncology.
  • Employees may experience changes as the company shifts its focus.
  • Customers of YUSIMRY will now be served by Meitheal Pharmaceuticals.
  • Suppliers may see changes in their relationships with Coherus.

Next Steps

  • Coherus will use the proceeds from the sale to advance its oncology pipeline.
  • Coherus will continue to provide transition services to HKF as per the Transition Services Agreement.
  • Coherus will focus on the commercialization of LOQTORZI and UDENYCA.
  • Coherus will continue the clinical development of its immuno-oncology pipeline.

Key Dates

DateDescription
March 1, 2024Date of the Confidentiality Agreement between Buyer and Seller.
June 15, 2023Surface Oncology executed a payoff arrangement to repay all amounts due under its loan and security agreement.
June 16, 2023Surface Oncology settled in full its payoff arrangement.
January 1, 2022Start date for the period of SEC reports referenced in the document.
July 1, 2023Start date for the period of SEC reports referenced in the document.
January 1, 2024Start date for the period of changes referenced in the document.
January 19, 2024Date of the Purchase and Sale Agreement between Coherus and Sandoz for the CIMERLI Disposition.
February 5, 2024Coherus entered into a Consent, Partial Release and Third Amendment with the lenders of the 2027 Term Loans.
March 31, 2024Date of the unaudited pro forma condensed combined balance sheet.
April 2024Coherus repaid $175.0 million of the existing principal balance of $250.0 million, plus the prepayment premium and makewhole amount totaling $6.8 million using proceeds from the CIMERLI Disposition.
May 8, 2024The remainder of the principal amounts outstanding under the 2027 Term Loans were paid off.
June 26, 2024Date of the Asset Purchase Agreement and closing of the YUSIMRY Disposition.
June 27, 2024Date of the press release announcing the completion of the YUSIMRY Disposition.

Keywords

YUSIMRY, Coherus BioSciences, Hong Kong King-Friend Industrial Company Ltd., divestiture, asset sale, oncology, adalimumab, Meitheal Pharmaceuticals, biosimilar

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.